- Prev close
- $902.90
- Day range
- $887.04 – $911.64
Regeneron’s sharp move is tied to its Q3 2026 earnings update and strong operating results, with the stock reaching its 52-week high of $935.35; the reaction looks well-supported by the numbers rather than driven by the broader market.
REGN
REGENERON PHARMACEUTICALS
As of Nov 1, 2026
78/100
Looks healthyHealth ScorePrimary driver
The move is primarily stock-specific: REGN rose +13.3% while the S&P 500 fell -1.8% and the Nasdaq 100 fell -3.5%, and its peers were much quieter at ABBV +1.4%, AMGN +1.1%, and GILD +3.1%. That gap says this was driven by Regeneron’s own earnings update and company news, not the market or the biotech group.
Volatility read
This is a larger-than-normal move, but it is backed by real operating strength rather than a fundamentals break. Revenue is up +9.3% YoY (TTM) and +16.7% YoY in the latest quarter, gross margin is 86.0%, operating margin is 24.7%, and net margin is 27.9%; valuation is 22.1 PE, 13.8 forward PE, and 1.16 PEG, with beta at 0.10. That combination says the business is healthy and the share price reaction is a response to earnings strength, though the 1.16 PEG shows investors are already paying for growth, which can make a strong rerating move more sensitive to future execution.
Next earnings setup
The next earnings date is 2027-01-28. The provided facts do not include formal consensus revenue or EPS growth expectations for that report, so I cannot quote a street estimate; what is known is that the company just posted third quarter 2026 revenue of US$5,115.8 million and net income of US$1,948.7 million, with the recent quarter showing +16.7% YoY revenue growth and margins of 86.0% gross, 24.7% operating, and 27.9% net. The market will be focused on whether Dupixent, EYLEA HD, and Libtayo can keep the current growth rate intact, whether the 22.1 PE / 13.8 forward PE remains justified, and how much additional support comes from share repurchases under the April 2026 buyback program.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track REGN with WhyIHold
Get a plain-English explanation the next time REGENERON PHARMACEUTICALS makes a big move — so you know whether it's benign or worth your attention.